Knowledge and Attitudes Concerning Aducanumab Among Older Americans After FDA Approval for Treatment of Alzheimer Disease

This survey study examines the understanding of aducanumab and attitudes toward its potential outcomes among older Americans after the drug's approval by the US Food and Drug Administration (FDA) for the treatment for Alzheimer disease.

Detalles Bibliográficos
Autores principales: Zissimopoulos, Julie, Jacobson, Mireille, Chen, Yi, Borson, Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8845005/
https://www.ncbi.nlm.nih.gov/pubmed/35157058
http://dx.doi.org/10.1001/jamanetworkopen.2021.48355
_version_ 1784651587016196096
author Zissimopoulos, Julie
Jacobson, Mireille
Chen, Yi
Borson, Soo
author_facet Zissimopoulos, Julie
Jacobson, Mireille
Chen, Yi
Borson, Soo
author_sort Zissimopoulos, Julie
collection PubMed
description This survey study examines the understanding of aducanumab and attitudes toward its potential outcomes among older Americans after the drug's approval by the US Food and Drug Administration (FDA) for the treatment for Alzheimer disease.
format Online
Article
Text
id pubmed-8845005
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-88450052022-02-18 Knowledge and Attitudes Concerning Aducanumab Among Older Americans After FDA Approval for Treatment of Alzheimer Disease Zissimopoulos, Julie Jacobson, Mireille Chen, Yi Borson, Soo JAMA Netw Open Research Letter This survey study examines the understanding of aducanumab and attitudes toward its potential outcomes among older Americans after the drug's approval by the US Food and Drug Administration (FDA) for the treatment for Alzheimer disease. American Medical Association 2022-02-14 /pmc/articles/PMC8845005/ /pubmed/35157058 http://dx.doi.org/10.1001/jamanetworkopen.2021.48355 Text en Copyright 2022 Zissimopoulos J et al. JAMA Network Open. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Research Letter
Zissimopoulos, Julie
Jacobson, Mireille
Chen, Yi
Borson, Soo
Knowledge and Attitudes Concerning Aducanumab Among Older Americans After FDA Approval for Treatment of Alzheimer Disease
title Knowledge and Attitudes Concerning Aducanumab Among Older Americans After FDA Approval for Treatment of Alzheimer Disease
title_full Knowledge and Attitudes Concerning Aducanumab Among Older Americans After FDA Approval for Treatment of Alzheimer Disease
title_fullStr Knowledge and Attitudes Concerning Aducanumab Among Older Americans After FDA Approval for Treatment of Alzheimer Disease
title_full_unstemmed Knowledge and Attitudes Concerning Aducanumab Among Older Americans After FDA Approval for Treatment of Alzheimer Disease
title_short Knowledge and Attitudes Concerning Aducanumab Among Older Americans After FDA Approval for Treatment of Alzheimer Disease
title_sort knowledge and attitudes concerning aducanumab among older americans after fda approval for treatment of alzheimer disease
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8845005/
https://www.ncbi.nlm.nih.gov/pubmed/35157058
http://dx.doi.org/10.1001/jamanetworkopen.2021.48355
work_keys_str_mv AT zissimopoulosjulie knowledgeandattitudesconcerningaducanumabamongolderamericansafterfdaapprovalfortreatmentofalzheimerdisease
AT jacobsonmireille knowledgeandattitudesconcerningaducanumabamongolderamericansafterfdaapprovalfortreatmentofalzheimerdisease
AT chenyi knowledgeandattitudesconcerningaducanumabamongolderamericansafterfdaapprovalfortreatmentofalzheimerdisease
AT borsonsoo knowledgeandattitudesconcerningaducanumabamongolderamericansafterfdaapprovalfortreatmentofalzheimerdisease

Ejemplares similares